SYNCROSOME
Combining Pharmacological Expertise with Optimal Design Studies

The global pharmaceutical industry has undergone monumental changes in the past few decades, and the prevalent adoption of outsourcing is one such change that has transformed the industry. Pharmaceutical outsourcing not only helps businesses reduce overhead and infrastructure costs but also enables them to improve the quality and reduce time-to-market. The increasing pressure on such businesses to improve their ROI has driven the pharma outsourcing industry. It is observed that pharma giants are favoring outsourcing vendors with end-to-end services. Amongst the plethora of pharmaceutical outsourcing companies in Europe, one name that cuts through the noise is SYNCROSOME. The Marseille-based company is the founding member of a high-tech network in the Eurobiomed healthcare cluster and offers R&D programs for developing new models and integrating new functional exploration methods.

SYNCROSOME was initially established to offer post-doctoral transitioning services through private sponsors with outsourcing requirements. The company’s offerings became massively successful in 2000, and SYNCROSOME became a simplified joint-stock company. Initially specialized in gastroenterology, the company, over the years, has gained proficiencies in pharmacokinetics, cardiovascular, central nervous system, metabolic, and respiratory diseases. SYNCROSOME collaborates closely with other member institutions of Eurobiomed to develop nascent series of compounds and drugs.

Owing to its flexible organization and teams of seasoned experts, SYNCROSOME has developed and validated more than 15 disease models. These scientific teams include biologists, veterinarians, PhDs, and technicians who offer very high levels of expertise in developing disease models across the various preclinical stages and anticipate critical endpoints after the in vitro screenings of their customers.

The company is well-known for designing and operating tailored experimental protocols and combining pharmacological expertise with optimal design studies, fundamentally offering highly reliable data to its clients. Apart from its primary services, SYNCROSOME primarily focuses on ethics, sustainable development, animal welfare, and the validation of data techniques. “We are actively involved in optimizing efficacy study designs on animal models to improve the success rate in phase 2 and thus reduce the drug-to-market cost,” says Richard Mitry, founder of SYNCROSOME. As a CRO specializing in in-vivo disease models, the company empowers its clients to organize, plan, and manage experiments and offers scientific expertise on pathologies and trends in the specific therapeutic niche. Committed to providing clients with reproducible results for various control groups of protocols, SYNCROSOME’s vast knowledge in a myriad of therapeutic areas proves to be a boon for pharmaceutical companies that are attempting to position or reposition their compounds. SYNCROSOME also offers simplified protocols to screen compounds on various primary and secondary therapeutic indicators. Though SYNCROSOME’s comprehensive and efficient services remarkably address the manifold challenges faced in the pharmaceutical industry, what differentiates it from its competitors is its approach to forming strong partnerships with its clients.

“With advanced techniques for selecting specific biomarkers while relying on strict procedures, trained people, and appropriate animal models, our team of outstanding professionals assist our customers in evaluating the potential of their compounds,” says Mitry. SYNCROSOME’s customer relations and scientific teams are available round the clock to guide their clients through their drug formulation and development processes, exceeding their expectations while ensuring their specific requirements are very well responded to. With such a customer-centric approach, SYNCROSOME has carved itself a niche in Europe’s pharmaceutical arena and consolidated its position as a reliable partner for pharmaceutical outsourcing requirements.